Changing concepts in multiple myeloma: from conventional chemotherapy to high-dose treatment

This publication has 39 references indexed in Scilit:

• Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
  New England Journal of Medicine, 1999
• Autologous peripheral blood progenitor cell transplantation for multiple myeloma
  Best Practice & Research Clinical Haematology, 1999
• Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma
  Bone Marrow Transplantation, 1999
• VAD or VMBCP in multiple myeloma refractory to or relapsing after cyclophosphamide–prednisone therapy (protocol MY 85)
  British Journal of Haematology, 1998
• CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
  British Journal of Haematology, 1998
• Phase I–II evaluation of rapid sequence tandem high-dose melphalan with peripheral blood stem cell support in patients with multiple myeloma
  Bone Marrow Transplantation, 1998
• VAD‐based regimens as primary treatment for multiple myeloma
  American Journal of Hematology, 1990
• INFUSION OF VINCRISTINE AND DOXORUBICIN WITH ORAL DEXAMETHASONE AS FIRST-LINE THERAPY FOR MULTIPLE MYELOMA
  The Lancet, 1989
• Multiple myeloma treated with high dose intravenous melphalan
  British Journal of Haematology, 1987
• Effective Treatment of Advanced Multiple Myeloma Refractory to Alkylating Agents
  New England Journal of Medicine, 1984